Can Iron Deposits Result from Intravenous Iron Infusions?
Yes, intravenous iron infusions definitively cause iron deposits in the liver, with a strong dose-dependent relationship between cumulative IV iron administration and hepatic iron accumulation.
Evidence of IV Iron-Induced Hepatic Iron Deposition
The evidence unequivocally demonstrates that IV iron therapy leads to liver iron accumulation:
Recent MRI studies of dialysis patients reveal a high frequency of iron overload with a strong link between cumulative IV iron dose and risk of hemosiderosis 1. This represents iatrogenic iron overload that was previously considered rare in the erythropoietin era but is now increasingly recognized 1.
Quantitative hepatic MRI and magnetic susceptometry studies show that liver iron concentration (LIC) directly correlates with total cumulative IV iron dose 1. The liver is the main storage site for iron, and LIC serves as the best surrogate marker for total body iron stores 2.
Autopsy studies confirm this relationship: chronic intravenous iron administration is associated with iron deposition in the liver, even at minimum recommended dosages 3. Liver biopsy specimens from dialysis patients receiving IV iron dextran showed that both histological iron scores and chemically measured liver iron concentrations depended on total cumulative iron dose 4.
Clinical Thresholds and Risk Stratification
The clinical significance of iron deposition follows established thresholds 1:
- Normal LIC: 32 μmol/g (95th percentile for healthy adults)
- MRI detection threshold: 50 μmol/g (upper limit of normal for dialysis patients)
- Treatment threshold: 125 μmol/g (increased risk of iron-induced complications; decision point for chelation therapy)
- Hepatic fibrosis risk: 160-331 μmol/g depending on underlying condition
Studies demonstrate that 50% of hemodialysis patients develop elevated liver iron concentrations from standard IV iron therapy 5. In one cohort, 80% of patients receiving IV iron showed some degree of hepatic iron overload (mild in 32.5%, moderate in 37.5%) 1.
Organ-Specific Deposition Patterns
Critical distinction: While hepatic iron deposition is common with IV iron therapy, cardiac iron deposition does not occur at standard therapeutic doses 5, 6. Multiple MRI studies confirm that the myocardium appears resistant to or protected against iron deposition, even when liver iron is significantly elevated. This contrasts with primary hemochromatosis or transfusion-related overload where cardiac involvement occurs at much higher iron burdens.
Monitoring Considerations
Important caveat: Serum ferritin and transferrin saturation correlate poorly with actual liver iron content in dialysis patients 6. These conventional markers are unreliable for detecting iron overload because:
- Ferritin is an acute phase reactant, elevated by inflammation independent of iron stores
- Transferrin saturation can be spuriously elevated immediately post-infusion due to circulating drug iron 7
MRI timing is critical: Different IV iron formulations interfere with MRI accuracy for varying durations 1:
- Iron sucrose, iron gluconate, ferric carboxymaltose: 1 week clearance
- Low-molecular-weight iron dextran, iron isomaltoside: 1 month
- High-molecular-weight iron dextran: 3 months
- Ferumoxytol: 6 months
Clinical Implications and Risk Management
The evidence reveals a concerning gap between current guidelines and actual risk:
Current anemia management guidelines (KDOQI-2006, KDIGO-2012) may not adequately protect patients from iron overload 1. The recommended IV iron doses in these guidelines can lead to clinically significant hepatic iron accumulation.
Three observational studies suggest that excessive IV iron doses may increase cardiovascular events and mortality in hemodialysis patients 1, though the mechanism remains debated (possibly through hepcidin dysregulation, oxidative stress from labile non-transferrin-bound iron, or other pathways).
Iatrogenic iron overload can occur even with newer formulations: A documented case of iron isomaltoside caused severe iron overload (ferritin 4336 ng/mL) after 7500 mg over 5 weeks, requiring 8 months of deferasirox chelation therapy 8.
Practical Approach
When administering IV iron:
- Use the minimum effective dose rather than aggressive repletion strategies
- Monitor cumulative dose - risk increases substantially above 4-5 grams total
- Consider MRI-based LIC measurement in patients receiving prolonged IV iron therapy, particularly if cumulative doses exceed recommended thresholds
- Recognize that standard iron markers (ferritin, TSAT) do not reliably detect or exclude iron overload in this population
- Time MRI appropriately based on the specific IV iron formulation used (see clearance times above)
The Japanese Society for Dialysis approach is notably conservative: limit IV iron to ≤650 mg in the induction phase, use only for true iron deficiency (ferritin <100 μg/L), and avoid routine maintenance IV iron therapy 1.
Bottom line: IV iron infusions unequivocally cause hepatic iron deposits in a dose-dependent manner, and current monitoring strategies using serum markers are inadequate to detect this accumulation before it reaches clinically significant levels.